Southern Shuanglin Bio-Pharmacy control change imminent

Southern Shuanglin Bio-Pharmacy [SZSE:000403] announced a significant potential shift in its control structure. On June 8, 2025, its controlling shareholder, Resun Investment, signed an "Acquisition Framework Agreement" with China National Biotec Group (CNBG). Resun Investment intends to transfer its 21.03% stake in Southern Shuanglin to CNBG. If the transaction proceeds successfully, CNBG will become the controlling shareholder, and the ultimate controller will shift from the Shaanxi Provincial People's Government's State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group.